Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675090 | 0.89 | TSHR (0.57) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL1464001 | 0.89 | TSHR (0.57) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL10488867 | 0.89 | TSHR (0.57) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL9652342 | 0.89 | TSHR (0.57) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL6672279 | 0.89 | TSHR (0.57) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL866951 | 0.87 | CYP3A4 (0.52) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL30932744 | 0.87 | CYP3A4 (0.52) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL616063 | 0.85 | ALDH1A1 (0.50) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL30291047 | 0.85 | CYP1A2 (0.53) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL18398966 | 0.85 | CYP1A2 (0.53) | CYP3A4TDP1ALDH1A1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-7214509-B2 | Methods and compositions for degradation of nitroaromatic and nitramine pollutants | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050054030-A1 | Methods and compositions for degradation of nitroaromatic and nitramine pollutants | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2005-03-10 | — | — | US | disclosed |
| WO-2005019136-A2 | METHODS AND COMPOSITIONS FOR DEGRADATION OF NITROAROMATIC AND NITRAMINE POLLUTANTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1172356-B1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6630598-B2 | Reacting nitroaniline compound with acid chloride/anhydride in presence of alkali metal/earth metal compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-07 | — | — | US | disclosed |
| EP-1172356-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-4323682-A | BLEACHING CATALYSTS | CIBA GEIGY AG (CH) | 1982-04-06 | — | — | US | disclosed |
| US-4202698-A | DYE BLEACH CATALYSTS | CIBA-GEIGY AG (CH) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CYP3A4 1201/4885TDP1 376/4885ALDH1A1 1899/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CYP3A4 1201/4885TDP1 376/4885ALDH1A1 1899/4885 |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | NAAA, NAT1, ACOT7 | CYP3A4 602/4885TDP1 3946/4885ALDH1A1 824/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | CYP3A4 1201/4885TDP1 376/4885ALDH1A1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.